Literature DB >> 9355836

MHC class II expression on human heart microvascular endothelial cells: exquisite sensitivity to interferon-gamma and natural killer cells.

R M McDouall1, P Batten, A McCormack, M H Yacoub, M L Rose.   

Abstract

BACKGROUND: Immunocytochemical analysis of human organs in situ reveals differential expression of MHC class II antigens by microvascular endothelial cells (MVEC) and endothelial cells (EC) from large vessels. In view of the role of EC as initiators of allograft rejection, it is of interest to understand the regulation of MHC class II regulation by human MVEC. We have previously isolated, cultured, and characterized MVEC from the human heart, showing that although these cells were initially MHC class II positive, the antigens were lost after about 14 days in culture. These results suggest that basal expression in vivo is maintained by circulating factors.
METHODS: Here we have compared the sensitivity of human heart MVEC, human umbilical vein endothelial cells (HUVEC), and adult large vessel EC (aorta, coronary artery, and pulmonary artery) to interferon (IFN)-gamma and natural killer (NK) cell-mediated induction of MHC class II antigens. MVEC and HUVEC were cultured with 1, 5, 10, 50, 100, and 500 U/ml of IFN-gamma for 4 days, the cells were washed, and flow cytometry was used to examine HLA-DR expression at days 1, 2, 4, 7, 10, 14, and 21. EC were also cultured with purified NK cells in the presence and absence of neutralizing antibodies to IFN-gamma, and MHC class II expression was analyzed.
RESULTS: As little as 5 U/ml of IFN-gamma produced 98% positive cells in heart MVEC compared with 100-500 U/ml needed for the same effect in HUVEC or other large vessel EC (coronary, aorta, pulmonary). Class II expression was maintained longer by MVEC (for 17 days) compared with HUVEC (for 10 days). NK cells and supernatant from MVEC/NK cultures induced MHC class II antigens on MVEC and HUVEC in a dose-dependent fashion; the MVEC showed an enhanced sensitivity compared with the HUVEC. The NK effects were inhibited by neutralizing antibodies to IFN-gamma. The allostimulatory ability of MHC class II-positive EC was shown to be proportional to the amount of MHC class II on the cell surface.
CONCLUSIONS: The results suggest that basal expression of MHC class II on human MVEC is maintained by circulating IFN-gamma and NK cells. This conclusion has implications for therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355836     DOI: 10.1097/00007890-199710270-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

3.  The interplay between the Rab27A effectors Slp4-a and MyRIP controls hormone-evoked Weibel-Palade body exocytosis.

Authors:  Ruben Bierings; Nicola Hellen; Nikolai Kiskin; Laura Knipe; Ana-Violeta Fonseca; Bijal Patel; Athina Meli; Marlene Rose; Matthew J Hannah; Tom Carter
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

4.  Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo.

Authors:  Jaehyuk Choi; Jason Walker; Sergei Boichuk; Nancy Kirkiles-Smith; Nicholas Torpey; Jordan S Pober; Louis Alexander
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model.

Authors:  Marguerite R Kelher; Anirban Banerjee; Fabia Gamboni; Cameron Anderson; Christopher C Silliman
Journal:  Transfusion       Date:  2016-09-25       Impact factor: 3.157

6.  Absence of donor-specific anti-HLA antibodies after ABO-incompatible heart transplantation in infancy: altered immunity or age?

Authors:  S Urschel; P M Campbell; S R Meyer; I M Larsen; J Nuebel; J Birnbaum; H Netz; K Tinckam; T Kauke; K Derkatz; J Y Coe; J L Platt; L J West
Journal:  Am J Transplant       Date:  2009-11-24       Impact factor: 8.086

7.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Methods Mol Biol       Date:  2013

8.  Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.

Authors:  Jie Hui Li; Martin S Kluger; Lisa A Madge; Lian Zheng; Alfred L M Bothwell; Jordan S Pober
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

9.  CD4 ligation on human blood monocytes triggers macrophage differentiation and enhances HIV infection.

Authors:  Anjie Zhen; Stephan R Krutzik; Bernard R Levin; Saro Kasparian; Jerome A Zack; Scott G Kitchen
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

10.  An alternative flow cytometry strategy for peripheral blood dendritic cell enumeration in the setting of repetitive GM-CSF dosing.

Authors:  Kehui Wang; Kevin P Nishimoto; Rita S Mehta; Edward L Nelson
Journal:  J Transl Med       Date:  2006-04-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.